Holder of an engineering degree from the Ecole Nationale Supérieure de Chimie de Paris (ENSCP), Larry ABENSUR also holds an MBA from INSEAD. For 9 years, he held various marketing positions in the pharmaceutical industry, as a Product Manager for biosynthetic human insulin at Eli Lilly, then as a Marketing Manager at UPJOHN France. For 6 years, he then took over the general management of PBS Orgenics, a player in in vitro diagnosis until its merger with Self Care (INVERNESS) and the introduction on the Nasdaq.
In 1993 and 1994, Mr. ABENSUR successively co-founded the All Diag and Dectra Pharm companies. In 2005, Larry ABENSUR participated in the creation of BIOSYNEX which he co-managed until October 2010. Since June 2015, Larry ABENSUR has been at the initiative of the creation of the BIOSYNEX group, the medtech leader in rapid diagnostic tests (RDTs), in which he currently holds the position of Chief Executive Officer.
After a first and a second cycle in pharmaceutical studies at the University of Paris V, Thierry PAPER completed a MBA at the Ecole Nationale des Ponts et Chaussées. He also holds a D.E.S (Diplôme d’Etudes Spécialisées) in medical biology from the University of Paris V.
An Intern in Pharmacy until May 1990, Thierry PAPER first joined the Israeli company Orgenics, where he held the positions of Project Manager and Marketing Manager. Between 1993 and 1997, he was in charge of the development of the French company Matara. From 1997 to 2005, he was an Assistant Director of the J-P Accary medical analysis laboratory. He was also a manager of Axodev, a business development services company for the in vitro diagnostics industry.
In 2005, Thierry PAPER participated in the creation of BIOSYNEX, of which he held the position of General and Operational Director. In June 2015, he became Deputy Managing Director of the BIOSYNEX group.
Graduate from an Agricultural Engineering program, Thomas LAMY also holds a PhD in Engineering from the National Polytechnic Institute of Lorraine since 1986. He also completed a MBA at the Ecole des Hautes Etudes Commerciales (HEC) in Paris.
After 4 successul years as Sales and Marketing Manager at Baker Instrument (a subsidiary of Johnson & Johnson), he joined the sales department of PBS Orgenics, a player in in vitro diagnosis, until its merger with Self Care (INVERNESS).
Thomas LAMY co-founded the All Diag and Dectra Pharm companies with Larry ABENSUR and was the CEO of All Diag from 1993 to 2015. In 2005, Thomas LAMY also participated in the creation of BIOSYNEX and actively contributed to the development of the company’s activities.
In June 2015, Thomas LAMY became Deputy Managing Director and from August 2022 he has held the position of Vice-President of the BIOSYNEX group.